Published in Cancer Detection and Prevention 1998; 22(2):147-152.

Shared Tumor Antigens in Colorectal Carcinoma and Neuroendocrine Tumors

Martin Tobi MB, ChBa, Elizabeth Darmon, MSa, Paul Rozen, MBBSa, Mimi Baratz, MDa, Monahill Lundqvist, PhDb, Kvell Oberg, MDb, Peter Thomas, Ph.Dc, Jose Esteban, MDd, Sian Hefta, Phdd, Ray Paxton, Ph.Dd, and Jack Shively, Ph.Dd

aDepartment of Gastroenterology and Pathology, Tel Aviv Medical Center, Sackler School of Medicine, Tel Aviv, Israel; bLudwig Institute for Cancer Research, Uppsala, Sweden; cNew England Deaconess Hospital, Harvard Medical School, Boston, MA; and dThe City of Hope National Cancer Center, Duarte, CA

Address all correspondence and reprint requests to: Marin Tobi, MB, ChB, Wayne State Medical School Division or Gastroenterology Harper Hospital, 3900 John R. St., Detroit, MI 48201.

ABSTRACT: ND4 monoclonal antibody recognizes a tumor marker found on poorly differentiated colorectal cancer. We demonstrate its expression in 25% of gastrointestinal neuroendocrine tumors, which also express CEA in 37% of cases. As in colorectal cancer die ND4 marker is predominantly membrane bound in a colonic neuroendocrine tumor cell line, LCC- 18 (p <0.05). The ND4 marker is absent in a poorly differentiated colorectal cancer cell line that docs not express CEA or other tumor antigens. Shed antigen in the serum of patients with neuroendocrine tumors is detected in only five of seven patients with the carcinoid syndrome and two of four of those without evidence or the syndrome. However, the reactivity was loss in the patients with localized disease, and this test is unlikely to be of diagnostic utility in this group of patients. The sharing of this antigen in colorectal cancer and neuroendocrine tumors is not universal, hut does support the common-cell progenitor theory for the origin of these tumors.

KEY WORDS: colon cancer, monoclonal antibodies, tumor markers.